Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3480 Peachtree Road NE , Second Floor, Suite 103 ATLANTA GA 30326 |
Tel: | N/A |
Website: | https://alzamend.com |
IR: | See website |
Key People | ||
William B. Horne Chairman of the Board | Stephan Jackman Chief Executive Officer, Director | Milton C. Ault Vice Chairman of the Board |
David J. Katzoff Chief Financial Officer | Henry C.W. Nisser Executive Vice President, General Counsel, Director | Kenneth S. Cragun Senior Vice President - Finance |
Business Overview |
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor. |
Financial Overview |
For the six months ended 31 October 2023, Alzamend Neuro Inc revenues was not reported. Net loss increased 5% to $6.4M. Higher net loss reflects Stock-based Compensation in R&D increase from $0K to $143K (expense), Other SGA increase of 54% to $184K (expense), Interest Expense increase of 20% to $6K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.95 to -$0.98. |